Chartwell Investment Partners’s Heron Therapeutics HRTX Stock Holding History

Chartwell Investment Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,171	Closed	-$1.86M	–	410
2019 Q2	$1.86M	Buy	100,171 +1,129	+1%	+$22.6K	0.06%	330
2019 Q1	$2.42M	Buy	99,042 +49,160	+99%	+$1.29M	0.08%	305
2018 Q4	$1.29M	Sell	49,882 -40,167	-45%	-$1.1M	0.05%	386
2018 Q3	$2.85M	Buy	90,049 +29,812	+49%	+$1.11M	0.08%	319
2018 Q2	$2.34M	Sell	60,237 -6,718	-10%	-$214K	0.07%	340
2018 Q1	$1.85M	Sell	66,955 -135,022	-67%	-$3.06M	0.06%	303
2017 Q4	$3.66M	Buy	201,977 +57,030	+39%	+$930K	0.12%	252
2017 Q3	$2.34M	Buy	+144,947	New	+$2.27M	0.08%	306

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Chartwell Investment Partners's HRTX Position: Q3 2019 in Review

Chartwell Investment Partners sold out of Heron Therapeutics (HRTX) in Q3 2019, closing a stake of 100,171 shares — an estimated $1.86M sold.

Chartwell Investment Partners first reported a position in HRTX in Q3 2017 and held it in 8 quarters. The position peaked at $3.66M in Q4 2017. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

Chartwell Investment Partners reported no remaining Heron Therapeutics position as of Q3 2019 after selling out during the quarter.
Chartwell Investment Partners sold 100,171 Heron Therapeutics shares in Q3 2019, an estimated $1.86M.
Chartwell Investment Partners first reported a position in Heron Therapeutics in Q3 2017 and held it in 8 quarters.
Chartwell Investment Partners's Heron Therapeutics position peaked at $3.66M in Q4 2017.
180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Chartwell Investment Partners's 13F filing for Q3 2019, filed 29 Oct 2019.